Weight Loss Drugs and Hair Loss: What Retatrutide's 24% Weight Loss Means

Weight Loss Drugs and Hair Loss: What Retatrutide's 24% Weight Loss Means

Hair loss is an emerging concern with GLP-1 receptor agonist weight loss drugs. Clinical trials and real-world data consistently show that the primary driver is not the specific drug, but the magnitude and speed of weight loss itself. Greater weight loss triggers more telogen effluvium — the medical term for stress-related hair shedding.

Retatrutide, the investigational triple agonist (GLP-1/GIP/glucagon), produced up to 24.2% mean weight loss in its Phase 2 trial — the highest of any weight loss drug tested to date. If weight loss magnitude is the primary driver of hair shedding, retatrutide users should expect the highest risk.

Retatrutide is an investigational drug that has not been approved by the FDA.

How Weight Loss Causes Hair Loss

The hair growth cycle

Hair follicles cycle through three phases:

  • Anagen (growth phase) — lasts 2-6 years; about 85-90% of hair is in this phase at any time
  • Catagen (transition phase) — lasts 2-3 weeks; the follicle shrinks and detaches from the blood supply
  • Telogen (resting phase) — lasts 2-3 months; the hair sits dormant before falling out and being replaced by new growth

What is telogen effluvium?

Telogen effluvium (TE) occurs when a physiologic stressor — such as rapid weight loss, surgery, illness, or severe caloric restriction — forces a large number of hair follicles from the anagen (growth) phase into the telogen (resting) phase simultaneously. Two to three months later, these hairs shed in a noticeable, diffuse pattern.

The hair matrix has one of the highest rates of cell turnover in the body. When the body is in significant caloric deficit, nutrient supply to the hair matrix is deprioritized. This disrupts normal follicle cycling and triggers premature entry into catagen and then telogen.

Why more weight loss means more hair loss

The relationship is dose-dependent — not on the drug dose, but on the amount of weight lost. Data from the Wegovy (semaglutide 2.4mg) STEP trials illustrate this clearly:

  • Participants who lost less than 20% of body weight: 2.5% experienced alopecia
  • Participants who lost more than 20% of body weight: 5.3% experienced alopecia — roughly double the rate

This pattern is consistent across all weight loss methods. Bariatric surgery patients, who typically lose 25-35% of body weight, report TE rates of 10-25%. The drug is not the direct cause — the caloric deficit and metabolic stress are.

Hair Loss Rates Across Weight Loss Drugs

DrugMechanismPhase 3 Weight LossClinical Trial Alopecia RatePlacebo Rate
Semaglutide 2.4mg (Wegovy)GLP-1~15-17%3-5.3%~1%
Tirzepatide 15mg (Zepbound)GLP-1/GIP~20-22%4-5.7%~1%
Retatrutide 12mgGLP-1/GIP/Glucagon~24% (Phase 2)Not separately reported*—

*Alopecia was not reported as a notable adverse event in the retatrutide Phase 2 trial (Jastreboff et al., NEJM 2023), but this was a relatively small trial (n=338) with limited statistical power to detect less common side effects. The Phase 3 TRIUMPH program, with thousands of participants, will provide definitive data.

The pattern is clear

More weight loss correlates with more hair shedding. Semaglutide produces ~15-17% weight loss and shows a 3-5% alopecia rate. Tirzepatide produces ~20-22% weight loss and shows a 4-6% rate. Retatrutide produces ~24% weight loss — the highest of any drug in clinical development — which strongly suggests its TE rate will be at the higher end of the range, or potentially higher.

What the Research Shows

FAERS pharmacovigilance data (Godfrey et al., JEADV 2025)

A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) from 2022-2023 found statistically significant signals for hair loss with both semaglutide and tirzepatide:

  • Semaglutide: Reporting Odds Ratio (ROR) of 2.46 (95% CI: 2.14-2.83)
  • Tirzepatide: ROR of 1.73 (95% CI: 1.42-2.09)
  • Older GLP-1 drugs (liraglutide, dulaglutide, exenatide): no significant signal

The higher ROR for semaglutide likely reflects longer market exposure and higher prescribing volumes rather than a genuinely higher per-patient risk. FAERS data cannot establish causation — it identifies signals worth investigating.

Real-world dermatology data (Burke et al., JAAD 2025)

A retrospective study at the University of Miami examined 283 dermatology patients on GLP-1 receptor agonists:

  • 15% experienced hair loss of any type
  • Diagnoses included androgenetic alopecia (7.7%), telogen effluvium (4.1%), and other types
  • Semaglutide showed a trend toward increased risk (OR 6.97, though with wide confidence intervals)
  • 83% of the cohort was on semaglutide, 46% on tirzepatide (some on both)

TriNetX cohort study (Vidal et al., JAAD International 2026)

The largest real-world study to date used the TriNetX U.S. Collaborative Network with 547,993 matched adult GLP-1 RA users and controls:

  • Telogen effluvium: adjusted odds ratio (aOR) of 1.76 at 12 months
  • Androgenetic alopecia: aOR of 1.64 at 12 months
  • Overall nonscarring hair loss: aOR of 1.40 at 12 months

This study confirmed that the association is real and not limited to case reports or pharmacovigilance signals.

What About Retatrutide Specifically?

Phase 2 data

The Phase 2 retatrutide trial (Jastreboff et al., NEJM 2023) did not report alopecia as a notable adverse event. However, this trial enrolled only 338 participants across multiple dose groups — far too small to reliably detect an adverse event that occurs in 3-6% of patients. The most commonly reported side effects were gastrointestinal (nausea, diarrhea, vomiting), consistent with the GLP-1 drug class.

What to expect from Phase 3

The TRIUMPH Phase 3 program enrolls thousands of participants and will provide the first robust safety data on retatrutide and hair loss. Given that:

  1. Telogen effluvium is driven primarily by weight loss magnitude
  2. Retatrutide produces the most weight loss of any drug in clinical development (~24%)
  3. Every other drug in this class shows dose-dependent alopecia rates that track with weight loss

It is reasonable to expect that retatrutide's alopecia rate will be at least comparable to tirzepatide's 4-6%, and potentially higher given the greater weight loss. This is not a deficiency of retatrutide — it is a predictable consequence of its superior efficacy.

The glucagon component — unknown variable

Retatrutide's glucagon receptor agonism is unique among advanced clinical candidates. Whether glucagon activity has any independent effect on hair follicle cycling — positive or negative — is unknown. There is no published research specifically examining glucagon receptor agonism and hair growth. This remains a data gap that the Phase 3 program may or may not address.

Prevention and Management Strategies

Telogen effluvium from weight loss is generally self-limiting — hair growth typically resumes once weight stabilizes, even if the drug is continued. However, the shedding period can last 3-6 months and cause significant distress. The following strategies may help reduce severity.

Adequate protein intake

The hair matrix requires amino acids for keratin synthesis. During rapid weight loss, protein requirements increase while appetite decreases — a problematic combination on GLP-1 drugs.

  • Target: 1.2-1.6g of protein per kilogram of body weight per day
  • Why it matters: GLP-1 drugs significantly reduce appetite, making it easy to undereat protein. Deliberate attention to protein-rich foods or supplementation is important
  • Key nutrients: Iron, zinc, biotin, vitamin D, and B vitamins also support hair health. A basic multivitamin may help address micronutrient gaps during caloric restriction

Gradual weight loss

Slower weight loss reduces the metabolic shock that triggers TE. Some clinicians recommend:

  • Slower dose escalation schedules
  • Maintaining adequate caloric intake even as appetite decreases (aim for no less than 1,200-1,500 calories per day)
  • Discussing rate-of-loss goals with your prescribing physician

Medical treatments

For patients experiencing significant hair shedding:

  • Minoxidil (topical) — the only FDA-approved over-the-counter treatment for hair loss. Available in 2% and 5% formulations. Can help support follicles during the shedding phase and may accelerate regrowth
  • Oral minoxidil (low-dose) — increasingly prescribed off-label by dermatologists for diffuse hair thinning
  • PRP (platelet-rich plasma) — some evidence for stimulating hair growth, though evidence quality is mixed and treatment is expensive
  • Spironolactone — may help if androgenetic alopecia is a contributing factor (women only)

When to see a dermatologist

Consult a dermatologist if:

  • Hair shedding is severe or persists beyond 6 months
  • You notice patchy (rather than diffuse) hair loss, which may indicate a different diagnosis
  • You have pre-existing hair thinning or a family history of androgenetic alopecia
  • Hair loss is causing significant distress and you want to discuss treatment options

What We Do Not Know Yet

  • Retatrutide Phase 3 alopecia rates have not been published. The TRIUMPH program will provide this data.
  • Whether retatrutide's glucagon activity has any independent effect on hair follicle cycling — positive or negative.
  • Long-term hair outcomes beyond 48-72 weeks on any GLP-1 drug. Most TE resolves, but the timeline for recovery during ongoing treatment is not well characterized.
  • Whether hair loss is fully reversible in all patients after weight stabilizes on drug.
  • Comparative rates between drugs at equivalent levels of weight loss. The existing data does not cleanly isolate drug mechanism from weight loss magnitude.

Frequently Asked Questions

Does retatrutide cause hair loss?

We do not have definitive data yet. The Phase 2 trial did not report alopecia as a notable adverse event, but the trial was too small (338 participants) to reliably detect it. Given that hair loss rates track closely with weight loss magnitude across all GLP-1 drugs, and retatrutide produces the most weight loss (~24%), it is reasonable to expect some degree of hair shedding. The Phase 3 TRIUMPH program will provide definitive data.

Is hair loss from weight loss drugs permanent?

Telogen effluvium — the type of hair loss caused by rapid weight loss — is generally self-limiting and reversible. Hair shedding typically occurs 2-3 months after significant weight loss begins, lasts 3-6 months, and resolves once weight stabilizes. Most patients experience full regrowth, though it can take 6-12 months after shedding stops. However, if you have pre-existing androgenetic alopecia (genetic pattern hair loss), the overall thinning may be more noticeable and slower to recover.

Which weight loss drug causes the least hair loss?

Among the advanced weight loss drugs, hair loss rates generally track with weight loss magnitude rather than specific drug mechanisms. Semaglutide (Wegovy) at ~15-17% weight loss shows ~3% alopecia. Tirzepatide (Zepbound) at ~20-22% weight loss shows ~4-6%. No drug has been shown to produce significant weight loss without some risk of telogen effluvium. The question is not which drug causes less hair loss, but how to manage the hair loss that accompanies substantial weight loss from any cause.

Can I prevent hair loss while taking GLP-1 drugs?

You can reduce the risk and severity, though you may not prevent it entirely. The most effective strategies are: adequate protein intake (1.2-1.6g/kg/day), ensuring sufficient micronutrients (iron, zinc, biotin, vitamin D), avoiding excessively rapid weight loss, and maintaining at least 1,200-1,500 calories per day. If shedding occurs, topical minoxidil may help support follicles during the transition. Talk to your doctor before starting any supplements.

Should I stop taking my weight loss medication if I notice hair loss?

Do not stop your medication without consulting your prescribing physician. Telogen effluvium is generally temporary and self-limiting — stopping the medication will not immediately reverse hair loss that has already been triggered (because the follicles entered the resting phase weeks earlier). Stopping may also lead to weight regain. Discuss with your doctor whether dose adjustment, nutritional optimization, or dermatologic treatment is more appropriate than discontinuation.

Sources

  • Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
  • Godfrey, H., et al. (2025). Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. Journal of the European Academy of Dermatology and Venereology (JEADV). DOI: 10.1111/jdv.20197
  • Burke, L.M., et al. (2025). Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study. Journal of the American Academy of Dermatology (JAAD). DOI: 10.1016/j.jaad.2025.01.051
  • Vidal, S.I., et al. (2026). Increased Incidence and Risk of Hair Loss with GLP-1 Receptor Agonists: A Real-World Multicenter TriNetX Cohort Study. JAAD International. DOI: 10.1016/j.jdin.2026.01.018
  • Wilding, J.P.H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2032183
  • Jastreboff, A.M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2206038

Medical Disclaimer

The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency.

If you are experiencing hair loss, consult with your healthcare provider or a dermatologist. Do not stop or modify your medication without medical guidance. Do not make changes to your treatment based on information about an unapproved drug.

This site is not affiliated with Eli Lilly and Company or any pharmaceutical manufacturer.